Fisher & Paykel Healthcare Corp. has announced results for the first half of its 2024 financial year.
For the sixth-month period ending Sept. 30, 2023, Fisher & Paykel Healthcare reported total operating revenue of $803.7 million. That’s a 16-percent increase from the prior corresponding period, the company said.
After taxes, net profits were $107.3 million, a 12-percent increase over the same time the previous financial year.
The Homecare product group — which includes products used to treat obstructive sleep apnea and provide respiratory support in patients’ homes — reported revenue of $314.4 million, a 26-percent increase from the previous corresponding period.
Fisher & Paykel Healthcare has approved an interim dividend of 18 cents per ordinary share, compared to 17.5 cent per share for the previous corresponding period.
Managing Director/CEO Lewis Gradon said in the announcement, ““Our first half result indicates a continuation of stable ordering patterns in our Hospital business and a robust performance for Homecare.”
He added that the company expects operating revenue for the 2024 financial year to be approximately $1.7 billion, with net profit after taxes to be in the $250 million to $260 million range.
Among its business highlights for the United States, Fisher & Paykel Healthcare listed regulatory clearance for the Airvo 3 Optiflow high flow therapy device and progressed product rollout, as well as launching the online Education Hub for clinicians in the United States.
